CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Sexually transmitted disease surveillance 2000 supplemen :; Gonococcal Isolate Surveillance Project (GISP) annual report, 2000
-
October 2001
Details:
-
Alternative Title:Gonococcal Isolate Surveillance Project (GISP) annual report, 2000;GISP 2000 surveillance supplement;
-
Personal Author:
-
Corporate Authors:
-
Description:"Gonorrhea is the second most frequently reported communicable disease in the United States. Gonorrhea rates in the United States declined 73.9% during 1975-1997. However, in 1998, the reported rate of gonococcal infections in the United States (131.6 cases per 100,000 persons) increased by 7.9% compared with the 1997 rate (122.0 cases per 100,000 persons). The gonorrhea rates in 1999 (132.0 cases per 100,000 persons) and 2000 (131.6 cases per 100,000 persons) were essentially unchanged from 1998. Gonorrhea rates remain high in the southeastern states, among minorities, and among adolescents of all racial and ethnic groups. The health impact of gonorrhea is largely related to its role as a major cause of pelvic inflammatory disease, which frequently leads to infertility or ectopic pregnancy. In addition, recent data suggest that gonorrhea facilitates HIV transmission. Control of gonorrhea has been complicated by the development of resistance to antimicrobial agents. The appearance of penicillinase-producing Neisseria gonorrhoeae (PPNG) and chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae (CMRNG) in the 1970s eventually led to the abandonment of these drugs as therapies for gonorrhea. The current CDC recommended primary therapies for gonorrhea are two broad-spectrum cephalosporins, ceftriaxone and cefixime, and two fluoroquinolones, ciprofloxacin and ofloxacin.7 However, fluoroquinolone-resistant N. gonorrhoeae have been reported from many parts of the world, including the United States." -- p. 1.
-
Content Notes:Division of STD Prevention, prepared by ... Susan A. Wang ... [et al.].
"October 2001."
Also available via the Internet.
Includes bibliographical references (p. 9-10).
-
Subjects:
-
Document Type:
-
Name as Subject:
-
Genre:
-
Place as Subject:
-
Pages in Document:print; iii, 22 p. : ill., maps ; 28 cm.
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: